OUP user menu

Guillain-Barré syndrome without sensory loss (acute motor neuropathy)
A subgroup with specific clinical, electrodiagnostic and laboratory features

L. H. Visser, F. G. A. Van Der Meché, P. A. Van Doorn, J. Meulstee, B. C. Jacobs, P. G. Oomes, R. P. Kleyweg
DOI: http://dx.doi.org/10.1093/brain/118.4.841 841-847 First published online: 1 August 1995


Summary We analysed data obtained from 27 out of a group of 147 patients with Guillain-Barré syndrome, who did not have sensory loss during a follow-up period of 6 months (motor Guillain-Barré syndrome). These patients had a distinctive clinical pattern compared with the other 120 Guillain-Barré syndrome patients. The clinical course was marked by a more rapid onset of weakness (3.9 versus 6.1 days, P = 0.002), an earlier nadir (6.3 versus 9.1 days, P < 0.001), an initially predominant distal weakness (67% versus 27%, P < 0.001), sparing of the cranial nerves (26% versus 68%, P < 0.001) and the disease was more often preceded by a gastro-intestinal illness (41% versus 13%, P = 0.001) often caused by a Campylobacter jejuni infection (67% versus 28% in the other Guillain-Barré syndrome patients, P < 0.001). High titres of anti-GMI antibodies were also significantly more common in motor Guillain-Barré syndrome patients (42% versus 5%, P < 0.001). Electromyographic data of the motor Guillain-Barré syndrome patients at nadir revealed little or no evidence for demyelination. Abundant denervation activity was present in half of the patients. The response to immune globulin treatment was good but with plasma exchange significantly fewer motor Guillain-Barré syndrome patients reached the stage of independent locomotion after a follow-up period of 6 months especially if the acute motor neuropathy occurred after a C. jejuni infection. The distinctive clinical, electrophysiological and laboratory features of motor Guillain-Barré syndrome patients show that the acute motor neuropathy represents a specific subgroup within the Guillain-Barré syndrome and recognizing these patients may have consequences for the choice of therapy.

  • Guillain-Barré syndrome
  • motor type
  • treatment
  • Campylobacter jejuni
  • anti-GMI antibodies

    Sign in

    Log in through your institution

    Sign in as a personal subscriber

    Log in through your institution

    Purchase a personal subscription